Pancreatic Cancer Research

ResearcherGeorgetown UniversityActive in the last 2 years

Louis M. Weiner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5192-0710; OpenAlex author ID A5045107557; NIH RePORTER profile ID 1871286. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 4)
Trials
0
Grants
1
Labs led
1
Collaborators
44
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: none · 2023: none · 2024: 3 papers · 2025: none · 2026: 1 paper, 1 grant

Papers 17

  1. Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-25-1481↗
  2. Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locall… Co-author DOI 10.1007/s12029-023-00996-3↗
  3. Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC). Co-author DOI 10.1016/j.ijrobp.2023.09.015↗
  4. The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers16030559↗
  5. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarci… Last author DOI 10.1136/jitc-2021-002837↗
  6. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance. Last author DOI 10.1158/2326-6066.cir-20-0272↗
  7. Understanding and Targeting Natural Killer Cell-Cancer-Associated Fibroblast Interactions in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers13030405↗
  8. T-Cell Immunity in Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001621↗
  9. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1301↗
  10. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1089/pancan.2019.0003↗
  11. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Last author DOI 10.1007/s00262-017-2077-9↗
  12. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/onc.2016.288↗
  13. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000118↗
  14. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-0149↗
  15. Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic c… Co-author DOI 10.3892/ol.2016.4101↗
  16. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-015-2855-z↗
  17. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcin… Co-author DOI 10.1097/coc.0b013e3181d2734a↗

Grants 1

  1. Cancer Host Interactions Program P30CA051008↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aiwu Ruth He · 7 shared papers, 2015–2024 · strength 0.73
  2. John Lindsay Marshall · 7 shared papers, 2015–2024 · strength 0.73
  3. Jeffrey A Toretsky · 1 shared grant, 2026 · strength 0.71
  4. Joyce Marie Slingerland · 1 shared grant, 2026 · strength 0.71
  5. Gary M Kupfer · 1 shared grant, 2026 · strength 0.71
  6. Giuseppe Giaccone · 1 shared grant, 2026 · strength 0.71
  7. Sharon J Levy · 1 shared grant, 2026 · strength 0.71
  8. Alexander A. Lekan · 2 shared papers, 2024–2026 · strength 0.69
  9. Zoe X. Malchiodi · 3 shared papers, 2021–2026 · strength 0.63
  10. Benjamin Adam Weinberg · 3 shared papers, 2020–2024 · strength 0.48
  11. Elana Judith Fertig · 3 shared papers, 2021–2026 · strength 0.46
  12. Keith Robert Unger · 3 shared papers, 2017–2024 · strength 0.43
  13. Emily R. Winslow · 2 shared papers, 2024 · strength 0.37
  14. Marcus Smith Noel · 2 shared papers, 2024 · strength 0.37
  15. Michael Jon Pishvaian · 5 shared papers, 2015–2020 · strength 0.36
  16. Reham Ajina · 2 shared papers, 2020–2021 · strength 0.35
  17. Ivana Peran · 1 shared paper, 2026 · strength 0.24
  18. Won Jin Ho · 1 shared paper, 2026 · strength 0.24
  19. Allison A. Fitzgerald · 2 shared papers, 2021 · strength 0.22
  20. Jimmy J. Hwang · 3 shared papers, 2015–2020 · strength 0.21
  21. Jonathan Robert Brody · 2 shared papers, 2019–2020 · strength 0.20
  22. Nicole Libbey · 1 shared paper, 2024 · strength 0.18
  23. Brandon George Smaglo · 1 shared paper, 2020 · strength 0.11
  24. Jill Palmer Smith · 1 shared paper, 2018 · strength 0.11
  25. Sandeep Nadella · 1 shared paper, 2018 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.